Efficacy and safety of intravenous iron sucrose, ferric carboxymaltose and iron isomaltoside in gynaecological patients: a comparative study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250512Keywords:
Ferric carboxy maltose, Haemoglobin, Iron deficiency anaemia, Iron isomaltoside, Iron sucrose, Serum FerritinAbstract
Background: Anaemia is a serious global public health problem that particularly affects young children, menstruating adolescent girls, pregnant and postpartum women. Parental iron therapy with iron sucrose or ferric carboxy maltose or iron isomaltoside results in faster and higher replenishment of iron stores with correction of Hb and ferritin levels and better patient compliance compared to oral drugs.
Methods: This was a prospective, randomized comparative study conducted over 18 months in Department of Obstetrics & Gynaecology, Hind Institute of Medical Science, Barabanki, Uttar Pradesh. Total of 87 female patients of age group 18-50 years with haemoglobin level of <10gm/dl and serum ferritin <100ng/dl in Gynaecology OPD and IPD were assigned to 3 groups of Iron Sucrose (IS) group, Ferric Carboxymaltose (FCM) group and Iron Isomaltoside (IIM) group. Each group included 29 women with a ratio of 1:1:1. Iron requirement was calculated by Ganzoni formula and parenteral iron was given intravenously. Baseline values of haemoglobin and serum ferritin was noted and repeated at the end of 4 weeks of therapy. The observed values were compared and analysed.
Results: The rise in haemoglobin and ferritin was higher with iron isomaltoside and ferric carboxymaltose (p value 0.000, statistically significant) when compared with iron sucrose group. However, rise was statistically not significant when compared between FCM and IIM group (for hemoglobin, p=0.32 and ferritin, p=8.18). The occurrence of adverse reactions was seen more commonly in iron sucrose but it was not found to be statistically significant.
Conclusions: The ability to deliver a high dose of iron within a short time, with single prick and less adverse effects make FCM and iron isomaltoside suitable for patients requiring quicker restoration of iron stores.
Metrics
References
Ministry of Health & Family Welfare Government of India. National Family Health Survey (NFHS-5)2019-21. Available at: https://mohfw.gov.in/sites/default/files/NFHS-5_Phase-II_0.pdf. Accessed 25 February 2024.
Kappert K, Jahić A, Tauber R. Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and non-infectious diseases. Biomarkers. 2020;25(8):616-25. DOI: https://doi.org/10.1080/1354750X.2020.1797880
Westad S, Backe B, Salvesen KA, Nakling J, Okland I, Borthen I, et al. A 12-week randomised study comparing intravenous iron sucroseversus oral ferrous sulphate for treatment of postpartum anaemia. Acta Obstet Gynecol Scand. 2008;87(9):916-23. DOI: https://doi.org/10.1080/00016340802317802
Rathod S, Samal SK, Mahapatra PC, Sama S. Ferric carboxymaltose: A revolution in the treatment of Post-partum anaemia Indian women Int J Appl Basic Med Res. 2015;5(1):25-30. DOI: https://doi.org/10.4103/2229-516X.149230
Tga.Gov.au. Monofer product information. Available at: https://www.tga.gov.au/sites/default/files/auspar-ferric_derisomaltose-181105-pi.pdf. Accessed 28 February 2024.
World Health Organization. Anaemia in women and children. Available at: https://www.who.int/data/gho/data/themes/topics/anaemia_in_women_and_children. Accessed 28 February 2024.
Cançado RD, de Figueiredo PO, Olivato MC, Chiattone CS. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. Rev Bras Hematol Hemoter. 2011;33(6):439-43. DOI: https://doi.org/10.5581/1516-8484.20110119
Naqash A, Ara R, Bader GN. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. BMC Womens Health. 2018;18(1):6. DOI: https://doi.org/10.1186/s12905-017-0506-8
Sharma N, Thiek JL, Natung T, Ahanthem SS. Comparative study of efficacy and safety of ferric carboxymaltose versus iron sucrose in post-partum anaemia. J Obstet Gynaecol India. 2017;67(4):253-257. DOI: https://doi.org/10.1007/s13224-017-0971-x
Derman R, Roman E, Smith-Nguyen GN, Achebe MM, Thomsen LL, Auerbach M. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia. Am J Hematol. 2018;93(6):E148-E150. DOI: https://doi.org/10.1002/ajh.25094
Harikrishnan P, Yanamandra U, Muthukrishnan J, Aggarwal D, Yadav A, Singh S, et al. P1495: A phase III, randomised controlled safety, efficacy and cost effectiveness trial of intravenous iron isomaltoside (i3r) and ferric carboxy maltose (feriumr) in subjects with iron deficiency anemia. Hemasphere. 2023;7(Suppl):e646858e. DOI: https://doi.org/10.1097/01.HS9.0000972860.64685.8e
Basha A, Ibrahim MIM, Hamad A, Chandra P, Omar NE, Abdullah MAJ, et al. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia. PLoS One. 2021;16(8):e0255104. DOI: https://doi.org/10.1371/journal.pone.0255104
Joshi SD, Chikkagowdra S, Kumar VC. Comparative study of efficacy and safety of intravenous ferric carboxy maltose versus iron sucrose in treatment of postpartum iron deficiency anaemia. Int J Reprod Contracept Obstet Gynecol. 2016;5(8):2566-70. DOI: https://doi.org/10.18203/2320-1770.ijrcog20162199
Kennedy NA, Achebe MM, Biggar P, Pöhlmann J, Pollock RF. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. Int J Clin Pharm. 2023;45(3):604-612. DOI: https://doi.org/10.1007/s11096-023-01548-2
Downloads
Published
How to Cite
Issue
Section
